New hope for rare ovarian cancer: immunotherapy drug tested in small trial
NCT ID NCT05737199
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug pembrolizumab in 21 women with a rare and advanced form of ovarian cancer called squamous cell carcinoma. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants receive the drug intravenously, and the study tracks how many respond and how long they live without the cancer getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Niigata University Medical & Dental Hosptal
Niigata, Niigata, 951-8510, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.